This is a study to evaluate the effects of perampanel, an FDA-approved drug for epilepsy, on commonly performed neurophysiology tests: electroencephalogram (EEG), somatosensory evoked potential (SEP), brainstem auditory evoked potential (BAEP), and visual evoked potential (VEP). Many other drugs used in the treatment of epilepsy have been shown to affect the results of these tests, but no one has yet examined if perampanel affects these tests.
The investigators plan to recruit 12 healthy normal male subjects. All subjects will have VEP, SEP, EEG, and BAEP performed before and 1 hour after receiving 6mg of oral perampanel. Subjects will also receive a blood draw 1 hour after ingestion of perampanel.
In a previous study done at another institution, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well. There is no placebo nor randomization. Subject's participation concludes after completion of post-perampanel ingestion neurophysiology tests.
Detailed eligibility will be reviewed when you contact the study team